No way [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2019-01-27 18:18 (913 d 03:05 ago) – Posting: # 19813
Views: 1,819

Dear yuvaneshwari,

» Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

» In the above scenario, can we consider for BCS based waiver approach ?

I think you have answered your own question. If solubility is the limiting factor, and your product has an improved solubility compared to the reference, how could you justify any kind of biowaiver ?

In any case: BCS-based biowaivers are only possible for class I and III products. Not the slightest chance if you're dealing with class II or IV.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,590 posts in 4,513 threads, 1,531 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).
Forum time: Wednesday 22:24 CEST (Europe/Vienna)

If a man will begin with certainties, he will end in doubts;
but if he will be content to begin with doubts,
he will end in certainties.    Francis Bacon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5